Dascena has obtained an Emergency Use Authorization (EUA) from the FDA for COViage, a machine learning algorithm that assists in the early detection of COVID-19 patients likely to experience symptoms such as low blood pressure or respiratory problems.

The algorithm works by analyzing patient data from electronic health records and gives healthcare providers advance notification of patients who are predicted to experience unstable blood pressure or a decline in respiratory function that requires mechanical ventilation. The EUA clears the software for use with adult patients by healthcare providers in hospitals.

“The early identification of patients at risk of respiratory decompensation or hemodynamic instability would enable physicians to more aggressively monitor these patients in a controlled environment and provide earlier treatment,” said Dascena’s CEO Ritankar Das.